A Single Oral Dose Study Of PF-06409577 In Healthy Adult Subjects
Status:
Terminated
Trial end date:
2015-06-01
Target enrollment:
Participant gender:
Summary
PF-06409577 is a new compound proposed for the treatment of diabetic nephropathy. The primary
purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of single
oral doses of PF-06409577 in healthy adult subjects.